Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses.

Autophagy Batten disease Lysosomal storage disease NCL Neurodegenerative disease Neuronal ceroid lipofuscinosis

Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 10 08 2019
revised: 12 10 2019
accepted: 14 10 2019
pubmed: 5 11 2019
medline: 22 12 2020
entrez: 4 11 2019
Statut: ppublish

Résumé

The neuronal ceroid lipofuscinoses (NCL) are a group of disorders defined by shared clinical and pathological features, including seizures and progressive decline in vision, neurocognition, and motor functioning, as well as accumulation of autofluorescent lysosomal storage material, or 'ceroid lipofuscin'. Research has revealed thirteen distinct genetic subtypes. Precisely how the gene mutations lead to the clinical phenotype is still incompletely understood, but recent research progress is starting to shed light on disease mechanisms, in both gene-specific and shared pathways. As the application of new sequencing technologies to genetic disease diagnosis has grown, so too has the spectrum of clinical phenotypes caused by mutations in the NCL genes. Most genes causing NCL have probably been identified, underscoring the need for a shift towards applying genomics approaches to achieve a deeper understanding of the molecular basis of the NCLs and related disorders. Here, we summarize the current understanding of the thirteen identified NCL genes and the proteins they encode, touching upon the spectrum of clinical manifestations linked to each of the genes, and we highlight recent progress leading to a broader understanding of key pathways involved in NCL disease pathogenesis and commonalities with other neurodegenerative diseases.

Identifiants

pubmed: 31678159
pii: S0925-4439(19)30294-7
doi: 10.1016/j.bbadis.2019.165571
pii:
doi:

Substances chimiques

Membrane Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

165571

Subventions

Organisme : Medical Research Council
ID : MC_U12266B
Pays : United Kingdom

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Elisabeth S Butz (ES)

Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Boston, MA 02114, USA.

Uma Chandrachud (U)

Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Boston, MA 02114, USA.

Sara E Mole (SE)

MRC Laboratory for Molecular Cell Biology and UCL GOS Institute of Child Health, University College London, London WC1E 6BT, United Kingdom.

Susan L Cotman (SL)

Center for Genomic Medicine and Department of Neurology, Massachusetts General Hospital Research Institute, 185 Cambridge St, Boston, MA 02114, USA. Electronic address: scotman@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH